CoChat
Sign Up
Cited by 358Bipolar Disorder and TreatmentTreatment of Major DepressionNerve injury and regeneration

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons

Yasuda, S, Liang, M-H, Marinova, Z, Yahyavi, A, Chuang, D-M·2009·Molecular Psychiatry
DOI 10.1038/sj.mp.4002099
Open this paper in CoChat — free account

Abstract

Brain-derived neurotrophic factor (BDNF) has been strongly implicated in the synaptic plasticity, neuronal survival and pathophysiology of depression. Lithium and valproic acid (VPA) are two primary mood-stabilizing drugs used to treat bipolar disorder. Treatment of cultured rat cortical neurons with therapeutic concentrations of LiCl or VPA selectively increased the levels of exon IV (formerly rat exon III)-containing BDNF mRNA, and the activity of BDNF promoter IV. Surprisingly, lithium- or VPA-responsive element(s) in promoter IV resides in a region upstream from the calcium-responsive elements (CaREs) responsible for depolarization-induced BDNF induction. Moreover, activation of BDNF promoter IV by lithium or VPA occurred in cortical neurons depolarized with KCl, and deletion of these three CaREs did not abolish lithium- or VPA-induced activation. Lithium and VPA are direct inhibitors of glycogen synthase kinase-3 (GSK-3) and histone deacetylase (HDAC), respectively. We showed that lithium-induced activation of promoter IV was mimicked by pharmacological inhibition of GSK-3 or short interfering RNA (siRNA)-mediated gene silencing of GSK-3alpha or GSK-3beta isoforms. Furthermore, treatment with other HDAC inhibitors, sodium butyrate and trichostatin A, or transfection with an HDAC1-specific siRNA also activated BDNF promoter IV. Our study demonstrates for the first time that GSK-3 and HDAC are respective initial targets for lithium and VPA to activate BDNF promoter IV, and that this BDNF induction involves a novel responsive region in promoter IV of the BDNF gene. Our results have strong implications for the therapeutic actions of these two mood stabilizers.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4002099

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Cited by

Sorted by citations

Items 301–358 of 358

Related

See all

Metadata

Authors
Yasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M.
Affiliations
National Institutes of Health (US)
Corresponding author
Chuang, D-M
Venue
Molecular Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2007-10-09
Volume
14
Issue
1
Pages
51-59
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
DOI
10.1038/sj.mp.4002099
OpenAlex
W2104411593
Cited by
358
References
48
Citations by year
2026: 3 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 14 · 2021: 14 · 2020: 14 · 2019: 16 · 2018: 16 · 2017: 19 · 2016: 21 · 2015: 27 · 2014: 32 · 2013: 34 · 2012: 26
FWCI
13.49
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Alliance for Research on Schizophrenia and Depression
  • National Institutes of Health
  • National Institute of Mental Health
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
brain-derived neurotrophic factor, BDNF promoter, lithium, valproic acid, mood stabilizers, glycogen synthase kinase-3, histone deacetylase, HDAC1, cortical neurons, neuronal depolarization, bipolar disorder, gene expression regulation
MeSH terms
Animals, Cells, Cultured, Cerebral Cortex, Dose-Response Relationship, Drug, Embryo, Mammalian, Enzyme Inhibitors, Enzyme-Linked Immunosorbent Assay, Membrane Potentials, Neurons, Potassium Chloride, Promoter Regions, Genetic, RNA, Messenger, Time Factors, Transfection, Valproic Acid, Lithium Chloride, Patch-Clamp Techniques, Antimanic Agents, Brain-Derived Neurotrophic Factor, RNA, Small Interfering, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review